The History of ProBeta

ProBeta® is the world’s most heavily tested, researched and refined Gymnema-sylvestre based product for maintaining healthy blood sugar levels.

Although the information here is technical in nature, we encourage all of our customers to read this information before buying our product, and at the bare minimum understand the graphs.

Our studies on ProBeta® were conducted on both Type-I and Type-II diabetics, as well on pre-diabetics.

ProBeta® on Fasting Blood Glucose, HbA1c & External Insulin

Type I Diabetics: Key Results from ProBeta® after six months

• 34% reduction in fasting blood glucose
• 22% reduction in HbA1c
• 14% reduction in external insulin requirement

Six patients diagnosed with Type I diabetes were administered one capsule of ProBeta® (200mg) three times a day along with their insulin. The following table shows, for each patient, the age and gender and length of Type I diabetes diagnosis, the daily dosage of insulin at the beginning of the ProBeta® treatment, as well as the daily insulin dosage following 3 months of treatment with ProBeta®, fasting blood glucose levels at 0, 3 and 6 months following treatment, as well as glycosylated hemoglobin (HbA1c) levels at 0, 3 and 6 months following ProBeta® therapy.

Half of the patients treated were able to reduce their daily insulin dosage during treatment with ProBeta®. In fact, patient 6, who had been diagnosed with Type I diabetes for only six months, was able to eliminate insulin administration all together following three months of treatment with ProBeta®. All patients experienced significant reductions in fasting blood glucose and glycosylated hemoglobin levels during treatment with ProBeta®, which are indicative of more effective glucose metabolism.

ProBeta® on Fasting Blood Glucose, HbA1c & External Insulin

Type II Diabetes: Key Results from ProBeta® after four months

• 23% reduction in fasting blood glucose
• 15% reduction in HbA1c

Six patients diagnosed with Type II diabetes were administered one capsule of ProBeta® (200mg) three times a day along with their other hypoglycaemic drugs for a treatment period of four months. The following table shows, for each patient, the age and gender and length of time of Type I diabetes diagnosis, the fasting blood glucose levels at 0, 2 and 4 months following treatment, and glycosylated hemoglobin (HbA1c) levels at 0, 2 and 4 months following ProBeta® therapy.

Most patients were able to decrease their other hypoglycemic drugs while on ProBeta® therapy.

Pre-Diabetics: Key Results from ProBeta® after four months

• 30% reduction in fasting blood glucose

HbA1C was not measured in this group, as the patients were only diagnosed with impaired glucose tolerance (ITG). Six patients diagnosed with impaired glucose tolerance (pre-diabetics) based on glucose tolerance tests were administered one capsule of ProBeta® (200mg) three times a day for 4 months. The age and gender of each of the patients and the fasting blood glucose levels at 0, 2 and 4 months following treatment with ProBeta® are shown in the table below. Treatment with ProBeta® resulted in significant reductions in fasting blood glucose levels in all cases.

ProBeta® on Blood Profile

Type I Diabetics: Blood profile after six months on ProBeta®

Data Observed: Cholesterol, triglycerides, free fatty acids, blood urea nitrogen, haemoglobin & c-peptile levels

Six patients diagnosed with Type I diabetes were administered one capsule of ProBeta® (200mg) three times a day along with their insulin for a four month period. The following table shows the effect of ProBeta® on cholesterol, triglycerides, free fatty acids, blood urea nitrogen, hemoglobin and c-peptide levels, and compares the pre-treatment and treatment levels with normal levels. These results are averaged for the six patients, with an average standard deviation of 10%.

Reduction in cholesterol, triglyceride, free fatty acid and blood urea nitrogen were observed. C-peptide levels increased significantly during ProBeta® therapy, indicating an increase in the production of endogenous insulin in Type I diabetic patients.

Type II Diabetics: Blood profile after four months on ProBeta®

Data Observed: Cholesterol, triglycerides, free fatty acids, blood urea nitrogen, hemoglobin, uric acid & postprandial insulin levels

Six patients diagnosed with Type II diabetes were administered one capsule of ProBeta® (200mg) three times a day along with their other hypoglycemic drugs for a four month period. The following table shows the effect of ProBeta® on cholesterol, triglycerides, free fatty acids, blood urea nitrogen, hemoglobin, uric acid and postprandial insulin levels, with a 10% average standard deviation. Significant reductions in cholesterol, triglyceride, free fatty acid and blood urea nitrogen were observed, and were accompanied by an increase in postprandial insulin levels. Results are show in the table above, and initial and final treatments are compared to normal levels.